Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Menadione Sulfurous Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.91 |
| ▸ | POLB | P06746 | 2/20 | 0.91 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Menadione Sulfurous Acid SCHEMBL461201 | 0.97 | MEN1 (0.91) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL29973176 | 0.97 | MEN1 (0.97) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL435171 | 0.97 | MEN1 (0.97) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL460403 | 0.95 | MEN1 (1.00) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL461612 | 0.95 | MEN1 (1.00) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL29364956 | 0.95 | MEN1 (1.00) | MEN1KMT2APOLBPARGALDH1A1 | |
| SCHEMBL18309831 | 0.83 | MEN1 (0.69) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL459525 | 0.81 | POLB (0.67) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL18314150 | 0.81 | POLB (0.67) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL459627 | 0.80 | POLB (0.65) | MEN1KMT2APOLBPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240398755-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | IC-MedTech Corp. | 2024-12-05 | — | — | US | disclosed |
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | IC-MedTech Corp. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | IC-MedTech Corp. | 2024-05-23 | — | — | US | disclosed |
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220409577-A1 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | IC-MedTech Corp. | 2022-12-29 | — | — | US | disclosed |
| US-20210361666-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | MARINGA STATE UNIVERSITY (BR) | 2021-11-25 | — | — | US | disclosed |
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC MEDTECH CORP (US) | 2021-09-16 | — | — | US | disclosed |
| US-20190343794-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | IC-MedTech Corp. | 2019-11-14 | — | — | US | disclosed |
| EP-3490543-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC-Medtech Corp. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20140200270-A1 | VITAMINS C AND K FOR TREATING POLYCYSTIC DISEASES | SUMMA HEALTH SYSTEM (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2014110305-A1 | VITAMINS C AND K FOR TREATING POLYCYSTIC DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014074765-A2 | VITAMIN C, VITAMIN K, A POLYPHENOL, AND COMBINATIONS THEREOF FOR WOUND HEALING | SUMMA HEALTH SYSTEM (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20130178522-A1 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE | SUMMA HEALTH SYSTEM | 2013-07-11 | — | — | US | disclosed |
| EP-2595615-A1 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE | Summa Health System (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120184609-A1 | VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR PROLONGATION OF PROSTHETIC IMPLANT | SUMMA HEALTH SYSTEM (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2475670-A1 | NEW (E)-STYRYL-ALKYNYLSUBSTITUTED SILICON COMPOUNDS AND METHOD OF OBTAINING (E)- STYRYL-ALKYNYLSUBSTITUTED SILICON COMPOUNDS | Adam Mickiewicz University (PL) | 2012-07-18 | — | — | EP | disclosed |
| EP-2456306-A1 | VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR PROLONGATION OF PROSTHETIC IMPLANT | Summa Health System (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012012370-A1 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE | SUMMA HEALTH SYSTEM (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011011317-A1 | VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR PROLONGATION OF PROSTHETIC IMPLANT | SUMMA HEALTH SYSTEM (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | SLC5A1, SLC5A2, SLC5A6 | MEN1 937/4885KMT2A 2743/4885POLB 3912/4885 |
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | MEN1 2407/4885KMT2A 3173/4885POLB 1341/4885 |
| US-20210361666-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | NQO1, ADH7, CYP27B1 | MEN1 2407/4885KMT2A 3173/4885POLB 1341/4885 |
| US-20220409577-A1 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | NDUFB7, NDUFA12, NDUFB11 | MEN1 1050/4885KMT2A 4149/4885POLB 1735/4885 |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | NQO1, ADH7, CYP27B1 | MEN1 2407/4885KMT2A 3173/4885POLB 1341/4885 |
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | NQO1, ADH7, TALDO1 | MEN1 2264/4885KMT2A 3016/4885POLB 1632/4885 |
| US-20130178522-A1 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE | PROC, NFKB2, NFKBIA | MEN1 1839/4885KMT2A 2706/4885POLB 2161/4885 |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | MEN1 2407/4885KMT2A 3173/4885POLB 1341/4885 |
| US-20190343794-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | NQO1, ADH7, TALDO1 | MEN1 2264/4885KMT2A 3016/4885POLB 1632/4885 |
| US-20120184609-A1 | VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR PROLONGATION OF PROSTHETIC IMPLANT | PROC, VKORC1, VKORC1L1 | MEN1 2175/4885KMT2A 3031/4885POLB 3084/4885 |
| US-20240398755-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | NQO1, ADH7, TALDO1 | MEN1 2264/4885KMT2A 3016/4885POLB 1632/4885 |
| US-20140200270-A1 | VITAMINS C AND K FOR TREATING POLYCYSTIC DISEASES | PROC, PKD1, VKORC1L1 | MEN1 527/4885KMT2A 3200/4885POLB 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.